About Philogen
Philogen is a company based in Sovicille (Italy) founded in 1996 by Dario Neri, Giovanni Neri, and Duccio Neri. It operates as a HealthTech and Licensing Model. Philogen has raised $69.7 million across 3 funding rounds from investors including European Union and The Equity Club. The company has 183 employees as of December 31, 2024. Philogen offers products and services including Nidlegy™, Fibromun, and OncoFAP Radio Conjugates. Philogen operates in a competitive market with competitors including Aclaris Therapeutics, MorphoSys, Escient Pharmaceuticals, Genmab and Nimbus Therapeutics, among others.
- Headquarter Sovicille, Italy
- Employees 183 as on 31 Dec, 2024
- Founders Dario Neri, Giovanni Neri, Duccio Neri
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Philogen Spa
-
Annual Revenue
$76.88 M (USD)219.91as on Dec 31, 2024
-
Net Profit
$47.05 M (USD)0as on Dec 31, 2024
-
EBITDA
$39.44 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$69.7 M (USD)
in 3 rounds
-
Latest Funding Round
$69.7 M (USD), Private Equity Round
May 13, 2019
-
Investors
European Union
& 1 more
-
Employee Count
183
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Philogen
Philogen is a publicly listed company on the MIL with ticker symbol PHIL in Italy, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Philogen
Philogen offers a comprehensive portfolio of products and services, including Nidlegy™, Fibromun, and OncoFAP Radio Conjugates.
A treatment for melanoma is developed by Philogen.
A targeted therapy is offered for cancer treatment.
Imaging and therapy solutions are provided for cancer.
Funding Insights of Philogen
Philogen has successfully raised a total of $69.7M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $69.7 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Philogen
Philogen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and The Equity Club.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment initiatives for companies are facilitated by The Equity Club.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Philogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Philogen
Investment portfolio details for Philogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Philogen
Detailed financials for Philogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Philogen Comparisons
Peer comparison for Philogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Philogen
Philogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, MorphoSys, Escient Pharmaceuticals, Genmab and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Antibody therapeutics for cancer and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
Detailed competitors of Philogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Philogen
Complete news archive for Philogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Philogen
Philogen was founded in 1996 and raised its 1st funding round 16 years after it was founded.
Philogen is headquartered in Sovicille, Italy. It is registered at Sovicille, Tuscany, Italy.
Dario Neri is the current CEO of Philogen. They have also founded this company.
Philogen is a funded company, having raised a total of $69.7M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Philogen is 183.
Annual revenue of Philogen is $76.88M as on Dec 31, 2024.
Philogen, a Swiss-Italian biotechnology company, is focused on innovating treatments for cancer and other serious conditions. The company is involved in the development of targeted therapies and imaging solutions within the healthcare sector. Products such as Nidlegy, Fibromun, and OncoFAP Radio Conjugates are developed to address specific cancer treatment needs. Research and development efforts are supported by enabling technologies and strategic partnerships. The company is listed on the Italian Stock Exchange and operates with a mission to advance therapeutic solutions.
Philogen's top competitors include Escient Pharmaceuticals, Forty Seven and Nimbus Therapeutics.
Philogen offers Nidlegy™, Fibromun, and OncoFAP Radio Conjugates.
Yes, Philogen is publicly traded on MIL under the ticker symbol PHIL.
Philogen has 2 investors. Key investors include European Union, and The Equity Club.
The ticker symbol of Philogen is PHIL on MIL.